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1 Introduction
In many species, including man, the second most
abundant lipid in lung surfactant is phosphatidyl-
glycerol (PG) which may comprise 10% or more
of the total lipid in surfactant from mature lungs
[20]. Interest in surfactant PG was stimulated by
the finding that surfactant obtained from tracheal
aspirates of full-term infants contained significant
amounts of PG while this lipid was absent from
the surfactant of premature infants [13]. Infants
delivered before their surfactant contained a large
amount of PG were at greater risk of succumbing
to hyaline membrane disease. During lung develop-
ment in the human and in other species, the PG
content of surfactant rises with a concomitant fall
in phosphatidylinositol (PI) content. It has been
proposed that the relative rates of synthesis of PI
and PG for surfactant may be influenced by the
availability of myo-inositol in the lung [3, 15]. In
many tissues, the limited amount of CDP-diacyl-
glycerol that is present likely restricts the bio-
synthesis of both PI and PG and it has been
observed in vitro that the metabolic fate of CDP-
diacylglycerol is influenced by the extracellular
concentration of myo-inositol [8, 10, 11]. It .has
been observed also that excess myo-inositol
administered to adult rabbits decreased surfactant
PG and increased surfactant PI [14]. We have
examined previously myo-inositol homeostasis in
the fetal rabbit [3] and in the human fetus [21],
Based on the results of those studies we concluded
that lung development in the human and in the
rabbit is accompanied by decreased availability of
myo-inositol for surfactant PI biosynthesis. In
addition, we observed that myo-inositol (in con-
centrations similar to those measured in vivo)
affected the incorporation of {14C} glycerol into
glycerophospholipids by fetal rabbit lung explants
[18] and by type II pneumonocytes isolated from
adult rat lung [4]. As the myo-inositol content of
the culture medium was increased, PI biosynthesis
was stimulated at the expense of PG biosynthesis.
In the present investigation myo-inositol was
administered chronically to nonpregnant rats and
to pregnant rats and the effect of this treatment
on the glycerophospholipid composition of lung
tissue and lung lavage was measured. In addition,
the influence of myo-inositol administration to
pregnant rats on the glycerophospholipid composi-
tion of lung tissue of their fetuses was investigated.
2 Materials and methods
i Sprague-Dawley rats were purchased from HOLTZ-
MAN (Madison, WI). The time of conception of the
pregnant rats was known to within 12 hours.
Throughout the experiment, the dams had free
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access to standard laboratory chow and drinking
water. For 5 days before sacrifice, the dams
received twice daily intraperitoneal injections of
myo-inositol (180mg) (SIGMA, St. Louis, MO)
or saline. The group of rats injected with myo-
inositol also had drinking water containing myo-
inositol (7% w/v.). Blood samples were obtained
from the tail vein of the rats and processed for
measurement of myo-inositol [3].
In experiments utilizing pregnant rats, the animals
were sacrificed on day 18 or day 21 of gestation
with a lethal dose of Nembutal. Fetuses were
removed quickly and fetal blood was obtained
from decapitated fetuses using a capillary pipette.
Fetal lungs were removed and kept at 4°C until
processed. In all studies, alveolar material was
obtained from adult animals by lavaging the lungs
with three 10ml aliquots of 0.9% NaCl via a
tracheal cannula. The lungs were then dissected
from the thorax and kept at 4°C until processed
further.
myo-inositol was measured in adult and fetal
blood by gas-liquid chromatography of its tri-
methylsilyl (TMS) derivative as described pre-
viously [3]. The amount of TMS-myo-inositol in
each extract was computed by measurement of
peak area relative to the peak areas obtained with
Tab. I. Effect on myo-inositol administration on concen-












313 ± 71 (4)**
234 ± 12 (8)
myo-inositol
456 ± 202(51)
670 ± 155 (72)
1177 ±198 (5)
517 ± 61 (6)
The values (Mean ± SE) for adult rats represent all meas-
urements obtained on days 1,3, and 5 of treatment. The
values (Mean ± SE) for fetuses represent pooled blood
from littermates. Numbers in parentheses are number of
determinations.
* .01 compared to saline treated pregnant rats
** .05 compared to saline treated day 21 fetuses
known amounts of authentic TMS-myo-inositol
(SIGMA). The values for serum myo-inositol con-
centration were corrected for total recovery of
tracer myo-(2-3H) inositol added to each initial
extract. Total recovery of the myo<2-3H) inositol
throughout the procedure ranged between 67 and
75%.
For determination of glycerophospholipid com-
position, lung lavage material was centrifuged
(600 g χ 10 min) at 4 °C and lipids were extracted
from the supernatant fluid and from lung tissue
homogenates as described elsewhere [2]. Phospho-
lipids were separated by 2-dimensional thin-layer
chromatography [23] and areas of thin-layer
chromatograms containing individual phospholipid
classes were transferred to test tubes. Lipid phos-
phorus was measured as described by AMES and
DUBIN [9].
3 Results
The concentration of myo-inositol in the serum of
pregnant rats was significantly higher than that in
nonpregnant rats (p < .01). Treatment of the rats
(pregnant and nonpregnant) with myo-inositol
resulted in elevated serum concentrations of myo-
inositol throughout the 5 days of the experiment
(Tab. I). Consistently, however, there was a tend-
ency for the serum myo-inositol concentration in
myo-inositol treated animals* to decrease over the
course of the experiment (Fig. 1). Between day
18 and day 21 of development, there was a signifi-
cant decrease in serum myo-inositol concentra-
tions in the fetuses of saline treated rats (p < .05).
Treatment of the pregnant dams with myo-inositol
resulted in a significant elevation in fetal serum
concentrations of myo-inositol on both day 18
and day 21 of gestation. Interestingly, however,
the concentration of myo-inositol in the serum of
fetuses of rats that received myo-inositol was still
greater on day 18 than on day 21, .and so was
analogous to the normal decline observed in
fetuses of the saline treated rats (Tab. I).
After 5 days of myo-inositol administration, the
glycerophospholipid composition of lung tissue
and lavage was analyzed. In both pregnant and
nonpregnant adult rats, there were significant
decreases in the PG content of lung tissue (p<.02)
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DAY OF T R E A T M E N T
Fig. 1. The effect of myo-inositol administration on the
serum concentration of myo-inositol in pregnant and non-
pregnant rats. Each bar represents the mean value ± S.E.
from between 17 and 25 measurements.
and lung lavage material (p < .01). These decreases
were associated with a significant increase in the PI
content of lung tissue (p < .01) and of lung lavage
material (p<.001). The phosphatidylcholine,
phosphatidylserine and phosphatidylethanolamine
content of adult lung tissues and lung lavage mate-
rial were not affected by myo-inositol administra-
tion (Tab. II). Although the administration of
myo-inositol to adult rats resulted in a decrease in
the PG content of their surfactant it did not
appear to affect drastically the health of these
animals. Nonpregnant adult rats treated with myo-
inositol had the same respiratory rate as the saline
treated rats and they maintained normal body
weight. Similarly, pregnant rats treated with myo-
inositol had normal respiratory rates, weight gains
and litter sizes (data not shown).
Having increased myo-inositol availability to the
fetuses of pregnant rats treated with myo-inositol,
the effect of this increased availability on the
glycerophospholipid composition of developing
fetal lung tissue was investigated. Between day 18
and day 21 of gestation, there was a significant
increase (p < .05) in the PG content (expressed as
percent of total glycerophospholipid) of lung
tissue obtained from fetuses of the saline treated
dams with a concomitant decrease in PI content
(p < .05). Administration of myo-inositol to preg-
nant rats for five days resulted in a significant
decrease in the PG content of fetal lung tissues at
both day 18 (p < .05) and day 21 (p < .01) of
gestation and a significant increase (p < .05) in
the PI content of lung tissues of day 21 fetuses
(Tab. HI), myo-inositol treatment had no effect
on the phosphatidylcholine, phosphatidylserine or
phosphatidylethanolamine content of fetal lung
tissues at day 18 or day 21 of gestation.
The effect of myo-inositol administration on
glycerophospholipid compositions was most strik-
ing when the phosphatidylglycerol to phosphatidyl-
inositol ratio (PG/PI ratio) of the different groups
was compared (Fig. 2). As expected, the PG/PI
ratio of lung lavage material was much higher than
Tab. II. Glycerophospholipid composition of adult rat lung tissue and lung lavage










































The data are expressed as mole percent of total glycerophospholipid (Mean < SE). (* P < .02, ** p < .01, *** p < .001,
when compared to rats treated with myo-inositol). Values for "other" phospholipids were calculated as the difference
between the total amount of lipid phosphorus applied to the thin-layer chromatography plate and the amount recovered
in the five glycerophospholipids listed above.
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Tab. III. Glycerophospholipid composition of fetal rat lung tissue










































The data are expressed as mole percent of total glycerophospholipid (Mean ± SE). (* p < .05 when compared to fetuses
of mothers treated with myo-inositol). Values for "other" phospholipids were calculated as the difference between the
total amount of lipid phosphorus applied to the thin-layer chromatography plate and the amount recovered in the five
glycerophospholipids listed above.
that of lung tissue. Treatment with myo-inositol
resulted in a highly significant (p < .001) decrease
in the PG/PI ratio in both lung tissue and in lung
lavage material of adult rats. The PG/PI ratio of
fetal lung tissue increased normally between day
18 and day 21 of gestation (p<.05) but the
administration of myo-inositol to pregnant rats
prevented this normal developmental increase in
the PG/PI ratio of lung tissues of their fetuses
(p < .05). Although the phosphatidylcholine,
2.0
in




















FETAL RAT LUNG TISSUE
Fig. 2. Phosphatidylglycerol: Phosphatidylinositol molar
ratios in adult and fetal lung tissues and adult lung lavage
in rats treated with myo-inositol or saline. Each bar
represents the mean value ± S.E. from the number of
measurements depicted adjacent to each bar (* p < .001;
** p < .05).
phosphatidylserine and phosphatidylethanolamine
content of adult and fetal lung tissues and lung
lavage material was unaffected by myo-inositol
treatment, the PG/PI ratios of adult lung tissues,
adult lung lavage, day 18 fetal lung tissues, and
day 21 fetal lung tissues were all reduced to very
similar low values.
4 Discussion
As part of an investigation1 of the influence of
myo-inositol on lung surfactant composition, preg-
nant and nonpregnant rats were treated with myo-
inositol. The concentration of myo-inositol in the
serum of pregnant rats was significantly greater
than that in the serum of nonpregnant rats.
Possible explanations for this finding include
increased myo-inositol biosynthesis in maternal
tissues and decreased renal clearance of myo-
inositol by the maternal kidney. Increased syn-
thesis is a likely possibility because myo-inositol
synthesis in several adult rat tissues is known to be
under hormonal control [17]. The putative rate
limiting enzyme in myo-inositol biosynthesis is
D-glucose 6-phosphate: 1 L-my o-inositol 1 -phos-
phate cyclase (cyclase) [9]. In the rat, cyclase
activity in primary and secondary sex organs is
regulated by pituitary hormones whereas cyclase
activity in the liver is regulated by thyroid hor-
J. Perinat. Med. 12 (1984)
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mones [17]. It is possible that gonadotropic studies involved short-term infusion of myo-
hormones synthesized during pregnancy might inositol. If the bulk of the administered myo-
exert an effect similar to that of pituitary hor- inositol is rapidly cleared from the maternal
mones. circulation by the kidneys, there may be only
In both pregnant and nonpregnant rats, treatment limited exposure of the fetus to high concentra-
with myo-inositol resulted in a marked increase in tions of myo-inositol. If the rate of uptake of
serum myo-inositol concentrations. Over the myo-inositol by the placenta is slow, a rather long
course of the 5 day treatment period, however, the exposure to large amounts of myo-inositol may
high concentration of myo-inositol in the serum of be required before a significant change in the
treated rats consistently declined toward normal, concentration of myo-inositol in fetal serum is
This may reflect altered renal metabolism or observed.
clearance of myo-inositol since in man at least, the It has been reported previously that the phos-
kidney is the major regulator of serum myo- phatidylethanolamine content of adult rat lung
inositol [7]. The human kidney both synthesizes tissue is greater than that reported here [22].
and oxidizes large amounts of myo-inositol and An explanation for this difference may be that
the rate of oxidation of myo-inositol appears to ethanolamine plasmalogen which co-chromato-
depend upon the plasma concentration of myo- graphs with phosphatidylethanolamine in most
inositol and renal plasma flow [7]. thin-layer Chromatographie systems may have been
The finding that the concentration of myo-inositol included with the total phosphatidylethanolamine
in fetal rat serum decreases between day 18 and measured in previous investigations. In the present
day 21 is consistent with previous observations in investigation, however, the acidic extraction con-
the rabbit [3] and in man [21] and is compatible ditions that were employed resulted in the hydro-
with the proposition that late in gestation there is lysis of ethanolamine plasmalogen and so it would
a decreasing availability of myo-inositol for PI not have contributed to the measured amounts of
biosynthesis in fetal rat lung, myo-inositol avail- phosphatidylethanolamine [16].
ability to the fetal lung may therefore be an The presence of myo-inositol in increased concen-
important regulator of the developmental change trations in maternal and fetal rat serum resulted in
from the production of a surfactant rich in PI to a significantly reduced PG/PI ratio in lung tissue
one rich in PG. The present observation that the m& iung iavage material without affecting the
concentration of myo-inositol in fetal rat serum amount of phosphatidylcholine, phosphatidyl-
declines at a time when the PG content of lung serine or phosphatidylethanolamine present. This
tissue increases is consistent with such a view, finding extends the previous observation that myo-
Similar changes in the extracellular concentration inositol administration to nonpregnant adult
of myo-inositol were found to affect the relative rabbits resulted in a decreased PG/PI ratio in lung
rates of synthesis of PI and PG by rat type II iavage material from adult lungs [14]. A reciprocal
pneumonocytes in vitro [4]. relationship between the synthesis of PG and that
Treatment of pregnant rats with myo-inositol of PI has been observed in several tissues [8, 11]
effected a significant elevation in myo-inositol and likely reflects competition for the limited
concentration in the serum of their fetuses at both amount of CDP-diacylglycerol that is the common
day 18 and day 21 of gestation. This most likely precursor of both these glycerophospholipids.
reflects transplacental uptake of myo-inositol Competition for CDP-diacylglycerol appears to be
although in previous studies employing sheep, no influenced by the availability of myo-inositol such
transplacental transport of -myo-inositol to the that an increase in the extracellular concentration
fetus could be detected when a large amount of of myo-inositol results in the stimulation of PI bio-
myo-inositol was administered in a single intra- synthesis at the expense of PG biosynthesis,
venous injection to the pregnant ewe [5, 19]. In In the present investigation, increasing myo-
addition to species differences, there are other inositol availability to the fetus prevented the pro-
possible reasons for this discrepancy. Previous duction of a surfactant characteristic of mature
J. Perinat. Med. 12 (1984)
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lungs, i.e., one rich in PG. This finding is com-
patible with the observation that PI synthesis is
favored over that of PG in rat type II pneuniono-
cytes in vitro when the extracellular concentration
of myo-inositol exceeds 300 μιη [4]. Although
that investigation was performed employing
type II pneumonocytes isolated from adult rats, it
was shown in another investigation that, at least in
the rabbit, the characteristics of myo-inositol
uptake by slices of adult and fetal lung are very
similar [3]. The present findings also complement
the observation that when insulin was infused into
pregnant rabbits the concentrations of glucose,
insulin, and myo-inositol in fetal serum were
decreased in association with the production by
the fetus of a lung surfactant enriched in PG
[15].
We speculate that myo-inositol may be involved
also in the delayed appearance of PG in the lung
surfactant of the human fetus in pregnancies com-
plicated by diabetes mellitus. Patients with dia-
betes mellitus are know to have myo-inositol
intolerance [6] and this has been implicated in the
etiology of diabetic neuropathy [12]. This intoler-
ance is corrected by insulin therapy [6]. The
imbalance in myo-inositol homeostasis in the preg-
nant diabetic woman might affect adversely myo-
inositol homeostasis in her fetus. Specifically,
increased placental transfer of myo-inositol
(resulting from high concentrations of myo-
inositol in maternal blood) and/or increased
synthesis de novo by the fetus (supported by
increased glucose availability to the fetus) might
result in a delay in the appearance of a lung
surfactant enriched with PG. The results of this
investigation support the hypothesis that factors
which affect myo-inositol homeostasis result in
an altered glycerophospholipid composition of
surfactant in adults and fetuses and justify an
examination of myo-inositol homeostasis in
human pregnancies complicated by diabetes
mellitus.
Summary
In many species including man, the second most abundant
lipid in lung surfactant is phosphatidylglycerol (PG)
which may comprise 10% of the total lipid in surfactant
from mature lungs. Infants delivered before their sur-
factant contained a large amount of PG are at greater risk
of succumbing to hyaline membrane disease. Regulation
of the PG content of lung surfactant is not understood
completely, but the reciprocal changes in the amount of
phosphatidylinositol (PI) and PG in surfactant as the lung
mature are suggestive of regulation at the level of a
common precursor.
The immediate common precursor of PI and PG is CDP-
diacylglycerol which is found in only small amounts in
most mammalian cells and likely restricts the biosynthesis
of both PI and PG. It has been observed in several species
that the enzymes that synthesize PI and PG compete for
the limited amount of CPD-diacylglycerol and this com-
petition is influenced by the availability of myo-inositol.
We and others have presented evidence that myo-inositol
availability in the developing lung may be an important
factor in the regulation of lung surfactant composition.
In the present investigation, myo-inositol was adminis-
tered chronically to nonpregnant and to pregnant rats and
the effect of this treatment on the glycerophospholipid
composition of lung tissue and lung lavage was measured.
In addition, the influence of myo-inositol administration
to pregnant rats on the glycerophospholipid composition
of lung tissue of their fetuses was investigated. The con-
centration of myo-inositol in adult and fetal blood was
measured by gas-liquid chromatography of its trimethyl-
silyl derivative. For determination of glycerophospholipid
composition, the total lipid extracts of lung tissues and
lung lavage were separated by 2-dimensional thin-layer
chromatography and quantified by lipid phosphorus assay
of individual spots.
The concentration of myo-inositol in the serum of preg-
nant rats was significantly higher than in nonpregnant rats
(Tab. I, Fig. 1). Treatment of the rats with myo-inositol
resulted in a significant elevation of serum concentrations
of myo-inositol throughout the experimental period.
Between day 18 and day 21 of the gestation there was a
significant decrease in serum myo-inositol concentrations
in fetuses of saline treated rats. Treatment of the preg-
nant dams with myo-inositol resulted in a significant
elevation in fetal serum concentrations of myo-inositol on
both day 18 and day 21 of gestation (Tab. I).
After 5 days of myo-inositol administration, the glycero-
phospholipid composition of lung tissue and lung lavage
was analyzed. In both pregnant and nonpregnant rats,
there was a significant decrease in the PG content of lung
tissue (p < .02) and lung lavage material (p < .01) asso-
ciated with a significant increase in their PI content
(p < .01 and ρ < .001, respectively). The content of other
measured glycerophospholipids was unaffected by treat-
ment (Tab. II).
Between day 18 and day 21 of gestation, there was signifi-
cant increase (p < .05) in the PG content with a con-
comitant decrease in PI content (p < .05) of lung tissue
obtained from fetuses of saline treated dams. Administra-
tion of myo-inositol to pregnant rats resulted in a signifi-
cant decrease in the PG content of fetal lung tissue on
day 18 (p < .05) and day 21 (p < .01) and a significant
J. Perinat. Med. 12 (1984)
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increase (p < .05) in the PI content of lung tissue of
day 21 fetuses (Tab. III).
The PG/PI ratio of the various groups were compared.
The ratio, as expected, was much higher for lung lavage
material than lung tissue in the adult rats. Similarly, the
PG/PI ratio in fetal lung tissue was higher on day 21 than
on day 18 of gestation. Following myo-inositol treat-
ment, the PG/PI ratio of adult lung tissue, adult lung
lavage, day 18 fetal lung tissue and day 21 fetal lung
tissue were all reduced to very similar ratios (Fig. 2).
These findings extend previous observations that myo-
inositol affects the PG and PI content of lung lavage
material. Competition for CDP-diacylglycerol appears
to be influenced by the availability of myo-inositol such
that an increased extracellular concentration of myo-
inositol results in the simulation of PI biosynthesis at
the expense of PG biosynthesis. We speculate that myo-
inositol may be involved in the delayed appearance of
PG in the lung surfactant of the human fetus in preg-
nancies complicated by diabetes mellitus. Patients with
diabetes are known to have myo-inositol intolerance that
is corrected by insulin therapy. Increased placental
transfer of myo-inositol (from high maternal blood con-
centrations) and/or increased synthesis de novo by the
fetus (supported by increased glucose availability) might
result in a delay in the appearance of a lung surfactant
enriched in PG.
Keywords: Fetal lung tissue, glycerophospholipids, myo-inositol, phosphatidylglycerol, phosphatidylinositol, rat
lungs lavage.
Zusammenfassung
Einfluß von Myo-inositol auf die Zusammensetzung der
Glycerophospholipide im Lungengewebe adulter bzw.
fetaler Ratten
Bei vielen Spezies, so auch beim Menschen, stellt das
Phosphatidylglycerol (PG) mit einem Anteil von 10% an
den Gesamtlipiden in der Surfactant reifer Lungen die
zweithäufigste Verbindung dar. Enthält die Surfactant
nicht ausreichende Mengen an PG, so ist das Risiko für
ein hyalines Membransyndrom erhöht. Wie der PG-Gehalt
in der oberflächenaktiven Substanz der Lunge reguliert
wird, ist nicht klar; da sich jedoch während der Lungen-
reifung Phosphatidylinositol (PI) und PG reziprok ver-
ändern, ist eine Regulation über eine gemeinsame Vor-
läufersubstanz anzunehmen.
Die unmittelbare Vorstufe von PI und PG ist das CDP-
Diacylglycerol, das in den meisten Säugerzellen nur in
geringen Mengen vorhanden ist und die Biosynthese von
PI und PG limitiert. Bei vielen Spezies wurde beobachtet,
daß die Synthese des CDP-Diacylglycerols über einen
kompetitiven enzymatischen Prozeß gesteuert wird und
dieser Prozeß von der verfügbaren Menge an Myo-inositol
abhängt. Wir und andere Arbeitsgruppen haben gezeigt,
daß während der Lungenreifung das Myo-inositol ein
wichtiger Faktor bei der Regulation der Surfactant-
zusammensetzung ist.
In der vorliegenden Untersuchung wurde Myo-inositol
kontinuierlich an nicht trächtige und trächtige Ratten
verabreicht. Wir haben den Einfluß dieser Behandlung auf
die Glycerophospholipidzusammensetzung im Lungen-
gewebe und in der Lungenlavage bestimmt. Dapriiber
hinaus untersuchten wir den Einfluß einer Myo-Inositol-
gabe an trächtige Ratten auf die Glycerophospholipid-
zusammensetzung im Lungengewebe der Feten. Die Myo.-
Inositolkonzentration im adulten wie im fetalen, Blut
wurde über eine Gas-Flüssigkeitschromatographie anhand
der Trimethylsilylderivate gemessen. Zur Bestimmung der
Glycerophospholipidzusammensetzung wurden die Ilipid-
extrakte aus dem Lungengewebe und der LungenlAvage
dünnschichtchroniatographisch aufgetrennt und die Spots
über einen Lipidphosphatansatz quantifiziert. l
Die Myo-Inositolkonzentration lag im Serum trächtiger
Ratten signifikant über der normaler Ratten (Tab. I,
Fig. 1). Die Myo-Inositolbehandlung führte zu einem
signifikanten Anstieg der Serumkonzentration über den
gesamten Untersuchungszeitraum. Zwischen dem 18.
und 21. Tag der Tragezeit kam es bei den Feten der mit
einer Salzlösung behandelten Ratten zu einem signifi-
kanten Abfall der Myo-Inositolkonzentrationen im
Serum. Die Behandlung der Muttertiere mit Myo-inositol
führte dagegen zu einem signifikanten Anstieg der Myo-
Inositolkonzentration im fetalen Serum sowohl am 18.
wie auch am 21. Tag der Tragezeit (Tab. I).
Nach fünftägiger Myo-Inositolgabe wurde die Glycero-
phospholipidzusammensetzung im Lungengewebe und in
der Lungenlavage analysiert. Sowohl bei trächtigen wie
auch bei normalen Ratten kam es zu einem signifikanten
Abfall des PG-Gehaltes im Lungengewebe (p < 0,02)
und im Material der Lungenlavage (p < 0,01); auf der
anderen Seite stieg der PI-Anteil signifikant an (p < 0,01
bzw. p < 0,001). Die Konzentrationen anderer Glycero-
phospholipide änderten sich unter der. Therapie nicht
(Tab. II).
Waren die Muttertiere mit einer Salzlösung behandelt,
stieg zwischen dem 18. und 21. Tag der Tragezeit der
PG-Gehalt im fetalen Lungengewebe signifikant an
(p < 0,05). Parallel dazu kam es zu einem Abfall des PI
(p < 0,05). Die Gabe von Myo-inositol an trächtige
Ratten führte dagegen zu einem signifikanten Abfall
des PG im fetalen Lungengewebe am 18. bzw. 21. Tag
(p < 0,05 bzw. p < 0,01) und zu einem Anstieg des PI
im Lungengewebe bei Feten am 21. Tag (Tab. III).
Wir haben die PG/PI-Ratio in den verschiedenen Gruppen
miteinander verglichen. Wie zu erwarten, war bei adulten
Tieren der Quotient im Lavagematerial viel größer als im
Lungengewebe. Ebenso lag die PG/PI-Ratio im fetalen
Lungengewebe am 21. Tag über der am 18. Tag. Nach
Myo-Inositolbehandlung waren die PG/PI-Quotienten von
adultem Lungengewebe und Lavage sowie von fetalem
Lungengewebe vom 18. und 21. Tag sämtlich auf ver-
gleichbare Werte reduziert (Fig. 2).
Diese Ergebnisse bestätigen die früheren Beobachtungen,
daß Myo-inositol eine Wirkung auf den PG- und PI-Gehalt
im Lavagematerial hat. Es scheint, daß die Konkurrenz
um das CDP-Diacylglycerol durch Myo-inositol beeinflußt
J. Perinat. Med. 12(1984)
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wird: eine erhöhte extrazelluläre Konzentration an Myo-
inositol stimuliert die PI-Biosynthese auf Kosten der
PG-Synthese. Bei diabetischen Schwangerschaften tritt
das PG in der Oberflächensubstanz fetaler Lungen ver-
zögert auf. Vielleicht kommt dabei dem Myo-inositol eine
Bedeutung zu. Diabetische Patienten haben nämlich ein
Myo-Inositolüberangebot, das durch die Insulintherapie
korrigiert wird. Ein vermehrter plazentarer Transport von
Myo-inositol (wegen hoher maternaler Konzentrationen)
und/oder eine erhöhte fetale de-novo-Synthese (wegen
eines vermehrten Glucose-Angebots) könnten dazu
fuhren, daß PG in der Surfactant nur verzögert ange-
reichert wird.
Schlüsselwörter: Fetales Lungengewebe, Glycerophospholipide, Myo-inositol, Phosphatidylglycerol, Phosphatidyl-
inositol, Rattenlungen-Lavage.
Resume
Effet du myo-inositol sur la composition des glycero-
phospholipides des extraits pulmonaires adultes et foetaux
chez le rat
Dans de nombreuses especes, y compris l'espece humaine,
le second lipide en abondance du surfactant pulmonaire
est le phosphatidylglycerol (PG) qui peut representer 10 %
des lipides totaux du surfactant au niveau des poumons
matures. Les enfants nes avant que leur surfactant con-
tienne une grande quantite de PG sont a plus haut risque
d'etre atteints d'une maladie des membranes hyalines. La
regulation de la teneur en PG du surfactant pulmonaire
n'est pas entierement comprise, mais les modifications
reciproques des quantites de phosphatidylinositol (PI) et
de PG suggerent qu'il existe une regulation au niveau d'un
precurseur commun.
Le precurseur commun immediat du PI et du PG est le
CDP-diacylglycerol qui n'est trouve qu'en faible abon-
dance dans les cellules de beaucoup manniferes, et ce
precurseur limite vraissemblablement la biosynthese ä la
fois du PI et du PG. On a observe dans de nombreuses
especes que les enzymes qui synthetisent le PI et le PG
utilisent de fagon competitive les quantites limitees de
CDP-diacylglycerol et cette competition est influencee par
la disponibilite de myo-inositol. Nous avons prouve ainsi
que d'autres auteurs que la disponibilite de myo-inositol
dans le poumon en croissance peut etre un facteur impor-
tant dans la regulation de la composition du surfactant
pulmonaire.
Dans ce travail, nous avons administre du myo-inositol de
fagon chronique ä des rattes gravides et non gravides et
nous avons mesure l'effet de ce traitement sur la composi-
tion des glycerophospholipides des tissus pulmonaires et
des liquides de lavage pulmonaire. En outre, nous avons
explore Finfluence de l'administration de myo-inositol ä
des rattes gravides sur la composition en glycerophos-
pholipided des extraits pulmonaires de leurs foetus. Nous
avons mesure la concentration de myo-inositol dans le
sang des adultes et des foetus par Chromatographie en
phase gazeuse et liquide de son derive trimethylsilyl. Pour
la determination de la composition des glycerophospho-
lipides nous avons separe les lipides totaux extraits des
poumons et des produits de lavage pulmonaire par Chro-
matographie ä 2 dimensions en couche mince et nous les
avons quantifies par dosage phospholipidique dans chaque
tache.
La concentration de myo-inositol dans le serum des rattes
gravides est significativement plus elevee que celle des
rattes non gravides (Tab. I, Fig. 1). Le traitement des
rattes avec du myo-inositol entraine une elevation signifi-
cative des concentrations seriques de myo-inositol tout au
long de Pexperimentation. Entre le 18eme jour et le
21eme jour de la gestation, il y a une diminution significa-
tive des concentrations de myo-inositol serique chez les
foetus de rattes traitees par du serum sale. Le traitement
des meres gravides par myo-inositol entraine une elevation
significative des concentrations foetales seriques de myo-
inositol ä la fois au ISeme et au 21eme jour de gestation
(Tab. I).
Au bout de 5 jours d'administration de myo-inositol, nous
avons analyse la composition des glycerophospholipides
des poumons et des liquides de lavage pulmonaire. Et
chez le rattes gravides et chez les rattes non gravides, il y a
une diminution significative de la teneur en PG des
poumons (p < 0,02) et des produits de lavage pulmonaire
(p < 0,01). Cette diminution est associee ä une augmen-
tation significative de leur teneur en PI (p < 0,01 et
p < 0,001, respectivement). La teneur des autres glycero-
phospholipides mesures n'a pas ete modifiee par le traite-
ment (Tab. II).
Entre le l Seme et le 21eme jour de gestation, il y a une
augmentation significative (p < 0,05) de la teneur en PG
avec une diminution concomittante de la teneur en PI
(p < 0,05) dans les poumons des foetus dont les meres
avaient ete traitees par du serum sale. L'administration de
myo-inositol aux rattes gravides entraine une diminution
significative de la teneur en PG des poumons foetaux a
J 18 (p < 0,05) et ä J 21 (p < 0,01) ainsi qu'une augmen-
tation significative (p < 0,05) de la teneur en PI des
poumons des foetus ä J 21 (Tab. III).
On a compare les rapports PG/PI des differents groupes.
Comme on s'y attendait, le rapport est plus eleve chez le
rat adulte dans les produits de lavage pulmonaire que dans
les poumons. De faqon similaire, le rapport PG/PI dans
les poumons adultes, dans les produits de lavage chez
Padulte, et dans les poumons foetaux ä J 18 et ä J 21 sont
tous diminues dans les proportions similaires (Fig. 2).
Ces donnees prolongent les observations anterieures qui
demontraient que le myo-inositol agit sur la teneur en PG
et PI du produit de lavage pulmonaire. La competition
pour le CDP-diacylglycerol apparait comme influencee par
la disponibilite du myo-inositol de teile sorte qu'une
elevation de la concentration extra-cellulaire de myo-
inositol entraine la stimulation de la bio-synthese de PI au
detriment de la bio-synthese de PG. Nous speculons que
peut impliquer le myo-inositol dans Fapparition
retardee du PG dans le surfactant pulmonaire du foetus
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humain au cours des grossesses compliquees de diabete
sucre. Les diabetiques sont connus pour avoir une intole-
rance au myo-inositol qui est corrigee par Tinsulino-
therapie. L'augmentation du transfert placentaire de
myo-inositol (a partir des concentrations sanguines
maternelles elevees) et/ou une augmentation de la syn-
these de novo par le foetus (grace ä une disponibilite
accrue du glucose) peut entralner un retard dans 1'appari-
tion du surfactant pulmonaire enrichi en PG.
Mots-cles: Glycerophospholipides, lavage pulmonaire chez le rat, myo-inositol, phosphatidylglycerol, phosphatidyl-
inositol, tissu pulmonaire foetal.
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